A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients

K. Fujiwara, A. Nagasaka, M. Nagata, K. Yamamoto, S. Imamura, N. Oda, Y. Sawai, N. Hayakawa, Atsushi Suzuki, Mitsuyasu Itoh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aims: To confirm whether a prostacyclin (prostaglandin 12) affects the increased TNF-α concentration in sera of diabetic patients, we measured serum TNF-α concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. Subjects and Methods: Serum TNF-α concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-α. Results: In diabetic patients, serum TNF-α concentration was significantly increased compared with that of healthy subjects. The augmented TNF-α concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin 12) analogue for 5 weeks without any changes of blood glucose levels. Conclusions: Stable prostacyclin analogue administration for a short term period reduced increased TNF-α levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.

Original languageEnglish
Pages (from-to)390-394
Number of pages5
JournalExperimental and Clinical Endocrinology and Diabetes
Volume112
Issue number7
DOIs
Publication statusPublished - 01-07-2004

Fingerprint

Epoprostenol
beraprost
Serum
Oral Administration
Synthetic Prostaglandins
Diabetic Neuropathies
Diabetes Complications
Hypoglycemic Agents
Prostaglandins
Blood Glucose
Epitopes
Healthy Volunteers
Monoclonal Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Fujiwara, K., Nagasaka, A., Nagata, M., Yamamoto, K., Imamura, S., Oda, N., ... Itoh, M. (2004). A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients. Experimental and Clinical Endocrinology and Diabetes, 112(7), 390-394. https://doi.org/10.1055/s-2004-821024
Fujiwara, K. ; Nagasaka, A. ; Nagata, M. ; Yamamoto, K. ; Imamura, S. ; Oda, N. ; Sawai, Y. ; Hayakawa, N. ; Suzuki, Atsushi ; Itoh, Mitsuyasu. / A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients. In: Experimental and Clinical Endocrinology and Diabetes. 2004 ; Vol. 112, No. 7. pp. 390-394.
@article{fbf1d994649f4dac9411156306582078,
title = "A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients",
abstract = "Aims: To confirm whether a prostacyclin (prostaglandin 12) affects the increased TNF-α concentration in sera of diabetic patients, we measured serum TNF-α concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. Subjects and Methods: Serum TNF-α concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-α. Results: In diabetic patients, serum TNF-α concentration was significantly increased compared with that of healthy subjects. The augmented TNF-α concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin 12) analogue for 5 weeks without any changes of blood glucose levels. Conclusions: Stable prostacyclin analogue administration for a short term period reduced increased TNF-α levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.",
author = "K. Fujiwara and A. Nagasaka and M. Nagata and K. Yamamoto and S. Imamura and N. Oda and Y. Sawai and N. Hayakawa and Atsushi Suzuki and Mitsuyasu Itoh",
year = "2004",
month = "7",
day = "1",
doi = "10.1055/s-2004-821024",
language = "English",
volume = "112",
pages = "390--394",
journal = "Experimental and Clinical Endocrinology and Diabetes",
issn = "0947-7349",
publisher = "Thieme",
number = "7",

}

Fujiwara, K, Nagasaka, A, Nagata, M, Yamamoto, K, Imamura, S, Oda, N, Sawai, Y, Hayakawa, N, Suzuki, A & Itoh, M 2004, 'A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients', Experimental and Clinical Endocrinology and Diabetes, vol. 112, no. 7, pp. 390-394. https://doi.org/10.1055/s-2004-821024

A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients. / Fujiwara, K.; Nagasaka, A.; Nagata, M.; Yamamoto, K.; Imamura, S.; Oda, N.; Sawai, Y.; Hayakawa, N.; Suzuki, Atsushi; Itoh, Mitsuyasu.

In: Experimental and Clinical Endocrinology and Diabetes, Vol. 112, No. 7, 01.07.2004, p. 390-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A stable prostacyclin analogue reduces high serum TNF-α levels in diabetic patients

AU - Fujiwara, K.

AU - Nagasaka, A.

AU - Nagata, M.

AU - Yamamoto, K.

AU - Imamura, S.

AU - Oda, N.

AU - Sawai, Y.

AU - Hayakawa, N.

AU - Suzuki, Atsushi

AU - Itoh, Mitsuyasu

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Aims: To confirm whether a prostacyclin (prostaglandin 12) affects the increased TNF-α concentration in sera of diabetic patients, we measured serum TNF-α concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. Subjects and Methods: Serum TNF-α concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-α. Results: In diabetic patients, serum TNF-α concentration was significantly increased compared with that of healthy subjects. The augmented TNF-α concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin 12) analogue for 5 weeks without any changes of blood glucose levels. Conclusions: Stable prostacyclin analogue administration for a short term period reduced increased TNF-α levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.

AB - Aims: To confirm whether a prostacyclin (prostaglandin 12) affects the increased TNF-α concentration in sera of diabetic patients, we measured serum TNF-α concentration and treated these patients with oral administration of the stable prostacyclin analogue (Beraprost). Twelve of 20 type II diabetic patients were investigated for follow up-study and 6 of those patients were for therapy with Beraprost for diabetic neuropathy. Subjects and Methods: Serum TNF-α concentration was quantified by EASIA using monoclonal antibodies directed against distinct epitopes of TNF-α. Results: In diabetic patients, serum TNF-α concentration was significantly increased compared with that of healthy subjects. The augmented TNF-α concentration in these patients was not decreased by diabetic control using antihyperglycemic agents for 8 weeks but was reduced with oral administration of a stable prostacyclin (prostaglandin 12) analogue for 5 weeks without any changes of blood glucose levels. Conclusions: Stable prostacyclin analogue administration for a short term period reduced increased TNF-α levels in diabetic patients, not through the improved hyperglycemic condition but another pathway, probably a cAMP system. These results imply that treatment with the prostacyclin analogue may contribute to the prevention of progression in diabetic complications.

UR - http://www.scopus.com/inward/record.url?scp=3142745646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142745646&partnerID=8YFLogxK

U2 - 10.1055/s-2004-821024

DO - 10.1055/s-2004-821024

M3 - Article

C2 - 15239025

AN - SCOPUS:3142745646

VL - 112

SP - 390

EP - 394

JO - Experimental and Clinical Endocrinology and Diabetes

JF - Experimental and Clinical Endocrinology and Diabetes

SN - 0947-7349

IS - 7

ER -